A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Trial Profile

A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Fluorouracil
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms SPECTRUM
  • Sponsors Amgen
  • Most Recent Events

    • 06 Mar 2014 According to ClinicalTrials.gov, status changed from active, no longer recruiting to completed.
    • 05 Jun 2013 Results published in Lancet Oncology.
    • 23 Sep 2011 Results will be presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology, according to an Amgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top